Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Solian 100 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White to off-white, round, flat-faced tablet engraved AMI 100 on one face and with a breakable bar on the other face. |
Each tablet contains 100 mg of the active substance, amisulpride.
Also contains 69.6 mg of lactose monohydrate.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Amisulpride |
Amisulpride is a neuroleptic. Amisulpride binds selectively with a high affinity to human dopaminergic D2/D3 receptor subtypes whereas it is devoid of affinity for D1, D4 and D5 receptor subtypes. |
| List of Excipients |
|---|
|
Sodium starch glycolate |
PVC/aluminium foil blister packs containing 30, 60 or 90 tablets.
Not all pack sizes may be marketed.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0651
Date of first authorisation: 6 July 1999
Date of latest renewal: 4 April 2007
| Drug | Countries | |
|---|---|---|
| SOLIAN | Austria, Australia, Cyprus, Germany, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Mexico, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
